SCHEMBL4293466

SCHEMBL4293466

Nc1cccc(Nc2nccc(Oc3ccc4c(ccn4-c4ccncc4)c3)n2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 2/20 0.48
BCR P11274 2/20 0.48
SRC P12931 2/20 0.48
CDK5 Q00535 2/20 0.45
KDR P35968 14/20 0.43
EGFR P00533 1/20 0.42
PRKACA P17612 1/20 0.42
PRKACG P22612 1/20 0.42
PRKACB P22694 1/20 0.42
RET P07949 2/20 0.39
FLT1 P17948 2/20 0.39
PDGFRB P09619 1/20 0.39
PDGFRA P16234 1/20 0.39
KDM4C Q9H3R0 1/20 0.39
SCN9A Q15858 1/20 0.39
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
CDK5R1 Q15078 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4285064 0.93 KDR (0.46) ABL1BCRSRCCDK5KDR
SCHEMBL4280981 0.92 ABL1 (0.48) ABL1BCRSRCCDK5KDR
SCHEMBL4279484 0.91 CDK5 (0.46) ABL1BCRSRCCDK5KDR
SCHEMBL4279410 0.91 MET (0.45) ABL1BCRSRCCDK5KDR
SCHEMBL4288896 0.90 CDK5 (0.46) ABL1BCRSRCCDK5KDR
SCHEMBL4279382 0.89 KDR (0.45) ABL1BCRSRCCDK5KDR
SCHEMBL4284798 0.89 CDK5 (0.46) ABL1BCRSRCCDK5KDR
SCHEMBL4287054 0.88 KDR (0.44) ABL1BCRSRCCDK5KDR
SCHEMBL4288235 0.88 CDK5 (0.45) ABL1BCRSRCCDK5KDR
SCHEMBL4285051 0.87 CDK5 (0.42) ABL1BCRSRCCDK5KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090149467-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-06-11 US claimed
EP-1934200-A1 TYROSINE KINASE INHIBITORS Merck & Co., Inc. (US) 2008-06-25 EP claimed
WO-2007035309-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-03-29 WO claimed
US-20090149467-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-06-11 US disclosed
US-20090149467-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-06-11 US disclosed
US-20090149467-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-06-11 US disclosed
EP-1934200-A1 TYROSINE KINASE INHIBITORS Merck & Co., Inc. (US) 2008-06-25 EP disclosed
WO-2007035309-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-03-29 WO disclosed
WO-2007035309-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149467-A1 Tyrosine Kinase Inhibitors ABL1, MET, ERBB2 ABL1 1/4885BCR 182/4885SRC 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.